Welcome to our dedicated page for Astrotech news (Ticker: ASTC), a resource for investors and traders seeking the latest updates and insights on Astrotech stock.
Astrotech Corp (ASTC) delivers cutting-edge solutions in chemical analysis and mass spectrometry through its 1st Detect and AgLAB divisions. This news hub provides investors and industry professionals with timely updates on technological advancements, strategic partnerships, and operational developments shaping security, agriculture, and analytical instrumentation markets.
Access official press releases, earnings reports, and market analyses in one centralized location. Track updates on trace detection systems for security applications, mass spectrometry innovations for agricultural optimization, and cross-industry collaborations driving ASTC's growth.
Our curated news collection covers:
- Product launch announcements
- Financial performance updates
- Research & development milestones
- Strategic partnership disclosures
- Industry recognition and patents
Bookmark this page for streamlined monitoring of ASTC's progress in commercializing scientific innovations. Verify timestamps on all materials and consult original SEC filings for complete disclosure details.
Astrotech Corporation (NASDAQ: ASTC) has entered an underwriting agreement with H.C. Wainwright & Co. for the firm purchase of 6,666,667 shares of common stock at $1.50 per share, aiming for approximately $10 million in gross proceeds. The offering is set to close around April 12, 2021, pending customary conditions. An additional 1,000,000 shares may be sold under a 30-day option. The funds will be used for general corporate purposes and capital expenditures. The offering is part of a shelf registration statement effective March 15, 2021.
Astrotech Corporation's subsidiary, BreathTech, has signed an Investigator-Initiated Study Agreement with Cleveland Clinic to use its BreathTest-1000™ for analyzing COVID-19 diagnosis via exhaled breath. The pilot study will compare breath samples between positive and negative COVID-19 PCR test subjects to evaluate volatile organic compounds (VOCs). Successful results may lead to FDA emergency use authorization for commercial use. The study is significant as it aims for early illness detection, with Cleveland Clinic's past research supporting VOC metabolite technology.
Astrotech Corporation (NASDAQ: ASTC) has announced a manufacturing agreement with Sanmina Corporation for its mass spectrometry products. After a thorough evaluation of contract manufacturing organizations, Astrotech's CEO expressed confidence in Sanmina's capabilities to support the company's growth plans. The agreement includes the production of 1st Detect's TRACER 1000™ and future manufacturing of AgLAB's AgLAB-1000™ and BreathTech's BreathTest-1000™ products.
Astrotech Corporation (NASDAQ: ASTC) reported financial results for Q2 FY2021, ending December 31, 2020, raising $37 million in gross proceeds to enhance growth. The company focuses on expanding its TRACER 1000 explosives trace detector sales, launching the AgLAB-1000-D2 in the hemp industry, and developing the BreathTest-1000 with The Cleveland Clinic Foundation. Notable achievements include exceeding $1 million in purchase orders for the TRACER 1000 and recognition with a Gold Award for CBRNE Detection. SG&A and R&D expenses were reduced significantly, contributing to improved financial flexibility.
Astrotech Corporation (NASDAQ: ASTC) has successfully completed a registered direct offering of 2,845,535 shares of common stock at a price of $3.25 per share, yielding approximately $9.25 million in gross proceeds. The funds will be utilized for ongoing operating expenses and working capital. The offering was facilitated by H.C. Wainwright & Co., under a previously established shelf registration statement with the SEC.
Astrotech Corporation (NASDAQ: ASTC) has announced a registered direct offering to institutional investors, selling 2,845,535 shares at $3.25 each, expecting gross proceeds of approximately $9.25 million, set to close around February 16, 2021. The funds will be allocated for operating expenses and working capital. H.C. Wainwright & Co. is the exclusive placement agent.
The offering is conducted under a previously filed shelf registration statement, and details will be included in a prospectus available through the SEC.
Astrotech Corporation (NASDAQ: ASTC) reported Q1 FY2021 results, highlighting strategic capital raises totaling $24.2 million to enhance growth opportunities. The company continues to market its TRACER 1000™ explosives trace detector, securing over $1 million in purchase orders. Significant advancements include non-detection testing completion with the TSA, positioning TRACER 1000 for approval. Furthermore, partnerships are established with Cleveland Clinic for the BreathTest-1000™, aimed at rapid infection screening. SG&A and R&D expenses are down, with a reduced monthly cash outlay of $493 thousand.
Astrotech Corporation (NASDAQ: ASTC) has successfully completed a registered direct offering of 2,887,906 shares of its common stock at $2.15 per share, totaling approximately $6.2 million in gross proceeds. The funds will support ongoing operating expenses and working capital. The offering was managed by H.C. Wainwright & Co., utilizing a previously filed shelf registration statement. This capital raise aims to bolster the company's financial standing as it continues to develop innovative technologies in various sectors.
Astrotech Corporation (NASDAQ: ASTC) announced a registered direct offering of 2,887,906 shares at $2.15 each, totaling gross proceeds of $6.2 million, expected to close around October 30, 2020. H.C. Wainwright & Co. is the exclusive placement agent for the offering. The funds will be allocated to ongoing operating expenses and working capital. This offering is conducted under a previously filed shelf registration statement with the SEC.
FAQ
What is the current stock price of Astrotech (ASTC)?
What is the market cap of Astrotech (ASTC)?
